Regeneron, Teva Report Positive Phase 3 Fasinumab Results

   By Colin Kellaher 
 

Regeneron Pharmaceuticals Inc. (REGN) and Teva Pharmaceutical Industries Ltd. (TEVA) on Thursday said a Phase 3 study of fasinumab in patients with chronic pain from osteoarthritis of the knee or hip met both co-primary endpoints and all key secondary endpoints.

The companies said fasinumab-treated patients experienced significantly less pain and significantly improved functional ability compared with placebo at the week-16 primary efficacy analysis.

Regeneron and Teva are jointly developing fasinumab, an investigational therapy invented by Regeneron, as part of a collaboration agreement they reached in 2016, with Teva making a $250 million upfront payment to Regeneron.

The Phase 3 study is a sub-study of a larger, long-term trial that involves 52 weeks of active treatment, designed to determine the safety and tolerability of fasinumab in pain from osteoarthritis of the knee or hip.

The companies said interim safety data showed the drug was generally well tolerated, with similar adverse events as those seen in previous trials.

Write to Colin Kellaher at [e-mail]

(END) Dow Jones Newswires

August 16, 2018 07:51 ET (11:51 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.